Diltiazem for SVT
Intravenous diltiazem is highly effective and appropriate for acute conversion of stable, narrow-complex supraventricular tachycardia when adenosine or vagal maneuvers fail or when SVT recurs after initial conversion. 1
Indications and Positioning in Treatment Algorithm
Diltiazem is a Class IIa recommendation for acute SVT treatment in hemodynamically stable patients 1. The treatment sequence should be:
- First-line: Vagal maneuvers, then adenosine (6 mg IV push, repeat with 12 mg if needed)
- Second-line: IV diltiazem or verapamil if rhythm remains uncontrolled, unconverted, or recurs
- Alternative: Use when beta blockers are contraindicated or not tolerated
Diltiazem demonstrates 64-98% conversion success rates for SVT 1, with one high-quality study showing 90% overall efficacy and 100% success in AV nodal reentrant tachycardia 2. The median time to conversion is approximately 2 minutes 2.
Dosing Protocol
Initial bolus: 15-20 mg (0.25 mg/kg) IV over 2 minutes 3, 1
Second bolus (if needed after 15 minutes): 20-25 mg (0.35 mg/kg) IV 3, 1
Maintenance infusion: 5-15 mg/hour, titrated to heart rate 3, 1
Critical technique note: A slow infusion up to 20 minutes may lessen hypotension risk 1. When the first bolus fails, the second bolus given after 5 minutes usually succeeds 4.
Absolute Contraindications
Per FDA labeling and guidelines, do NOT use diltiazem in 5:
- Wide-complex tachycardia or ventricular tachycardia (can cause hemodynamic collapse and ventricular fibrillation)
- Pre-excited atrial fibrillation/flutter (WPW syndrome, accessory pathways) - may cause life-threatening ventricular rate acceleration
- Decompensated heart failure or systolic dysfunction
- Hypotension or cardiogenic shock
- Second- or third-degree AV block (without pacemaker)
- Sick sinus syndrome (without pacemaker)
- Concurrent or recent IV beta-blocker use (within a few hours) - risk of profound bradycardia 3, 5
Critical Safety Considerations
Ensure narrow-complex tachycardia before administration 3. The most dangerous pitfall is administering diltiazem for wide-complex tachycardia that is actually ventricular tachycardia—this can precipitate ventricular fibrillation 1, 5.
Monitor for adverse effects 3, 1:
- Hypotension (most common)
- Bradycardia
- Worsening heart failure
- Abnormal liver function (rare with short-term use)
Adverse events occur in approximately 6-11% of patients when protocols are followed 2, 6, but increase to 18% when given outside protocol parameters 6.
Mechanism and Efficacy
Diltiazem works by slowing AV nodal conduction and increasing AV nodal refractoriness, effectively terminating reentrant SVTs that depend on the AV node 5, 2. It has no effect on accessory pathways, which is why it's contraindicated in pre-excited rhythms 2.
Comparative effectiveness: Diltiazem is significantly more effective than esmolol for SVT conversion 4 and shows equivalent efficacy to verapamil 7, 8. While adenosine remains first-line due to its safety profile and diagnostic utility, diltiazem offers the advantage of a longer duration of action, reducing recurrence rates 3.
Hemodynamically Unstable Patients
Do NOT use diltiazem in unstable patients 1. Proceed directly to synchronized cardioversion for SVT causing hypotension, altered mental status, shock, chest pain, or acute heart failure 1. Adenosine may be attempted first if the rhythm is regular narrow-complex and preparations for cardioversion are underway 1.